Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page's revision tag updated from v3.5.3 to v3.5.4, indicating a minor update to the study details page metadata. This reflects an internal revision rather than changes to the study data or content.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedUpdates the Chile location listing to use shorter region labels (e.g., Araucania and Valparaiso) alongside the corresponding city/state entries, and updates the displayed site revision version.SummaryDifference0.4%

- Check37 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded Padova, Italy, 35128 as a study location and removed Padua, Italy, 35128.SummaryDifference0.0%

- Check59 days agoChange DetectedThe Italian trial site entry was updated from Napoli, Italy, 80131 to Naples, Italy, 80131.SummaryDifference0.0%

- Check66 days agoChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.